%0 Journal Article
%A Qadir, Muhammad Imran
%A Zafar, Maria
%D 2017
%I Begell House
%K tumor susceptibility gene 101 (tsg101), HIV, monoclonal antibody, CB8-2, HIV/AIDS therapy, UEV,
TSG101
%N 3
%P 237-246
%R 10.1615/CritRevEukaryotGeneExpr.2017019418
%T TSG101: Tumor Susceptibility Gene 101 (tsg101) Product−Role in Therapy Against HIV/AIDS
%U https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,3e1db9ff199ae23c,171ce94b0b6a30d5.html
%V 27
%X HIV infection presents a major community health hazard, partially because the HIV virus is capable
of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however,
some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might
be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as
a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on
their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2
lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed
antibodies to fight against AIDS.
%8 2017-09-29